| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 26 | 2022 | 7240 | 2.000 |
Why?
|
| Ceramides | 11 | 2016 | 97 | 1.860 |
Why?
|
| Protein Phosphatase 2 | 9 | 2018 | 90 | 1.810 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 21 | 2016 | 1547 | 1.780 |
Why?
|
| Galectin 3 | 3 | 2019 | 133 | 1.640 |
Why?
|
| Apoptosis | 33 | 2022 | 7852 | 1.430 |
Why?
|
| Nitrophenols | 6 | 2021 | 95 | 1.240 |
Why?
|
| Tumor Microenvironment | 7 | 2018 | 2984 | 1.200 |
Why?
|
| Biphenyl Compounds | 6 | 2021 | 192 | 1.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 9 | 2021 | 582 | 1.100 |
Why?
|
| Galectins | 4 | 2019 | 73 | 1.050 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2022 | 5411 | 0.960 |
Why?
|
| Phosphoprotein Phosphatases | 5 | 2018 | 223 | 0.960 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 6 | 2022 | 289 | 0.870 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2022 | 28 | 0.820 |
Why?
|
| Sulfonamides | 7 | 2022 | 1922 | 0.810 |
Why?
|
| Protein Kinase C | 7 | 2011 | 420 | 0.780 |
Why?
|
| Phosphorylation | 23 | 2018 | 4986 | 0.770 |
Why?
|
| Galectin 1 | 1 | 2020 | 20 | 0.720 |
Why?
|
| CD27 Ligand | 1 | 2019 | 23 | 0.670 |
Why?
|
| Protein Kinase C-alpha | 7 | 2014 | 68 | 0.670 |
Why?
|
| Cell Death | 2 | 2021 | 689 | 0.650 |
Why?
|
| Immunologic Surveillance | 2 | 2015 | 61 | 0.650 |
Why?
|
| Signal Transduction | 19 | 2021 | 12207 | 0.640 |
Why?
|
| Immunity | 1 | 2021 | 356 | 0.630 |
Why?
|
| Leukemia, Myeloid | 6 | 2018 | 994 | 0.630 |
Why?
|
| Stem Cell Niche | 1 | 2018 | 94 | 0.600 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 4 | 2008 | 309 | 0.590 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2022 | 4956 | 0.590 |
Why?
|
| Virus Diseases | 1 | 2021 | 392 | 0.580 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 685 | 0.560 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2017 | 157 | 0.550 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2022 | 996 | 0.530 |
Why?
|
| Neoplastic Stem Cells | 7 | 2019 | 1469 | 0.530 |
Why?
|
| Naphthoquinones | 1 | 2015 | 19 | 0.510 |
Why?
|
| Leukemia | 5 | 2017 | 1722 | 0.510 |
Why?
|
| Gossypol | 1 | 2015 | 28 | 0.500 |
Why?
|
| Cell Survival | 12 | 2020 | 3082 | 0.490 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2017 | 2093 | 0.480 |
Why?
|
| Polysaccharides | 1 | 2015 | 196 | 0.480 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2022 | 841 | 0.470 |
Why?
|
| Up-Regulation | 5 | 2018 | 2465 | 0.460 |
Why?
|
| Cell Line, Tumor | 20 | 2022 | 14864 | 0.450 |
Why?
|
| Oleanolic Acid | 4 | 2008 | 112 | 0.440 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2020 | 3657 | 0.430 |
Why?
|
| Imidazoles | 4 | 2016 | 1060 | 0.420 |
Why?
|
| Antineoplastic Agents | 18 | 2021 | 14678 | 0.420 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 4 | 2022 | 474 | 0.410 |
Why?
|
| Neoplasm Proteins | 6 | 2020 | 3349 | 0.410 |
Why?
|
| Mitochondria | 10 | 2016 | 1319 | 0.410 |
Why?
|
| Quinoxalines | 1 | 2012 | 98 | 0.390 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 250 | 0.380 |
Why?
|
| Tumor Cells, Cultured | 13 | 2018 | 5835 | 0.360 |
Why?
|
| Caspases | 4 | 2014 | 701 | 0.360 |
Why?
|
| Inflammation | 2 | 2021 | 2526 | 0.350 |
Why?
|
| RNA, Small Interfering | 6 | 2020 | 2214 | 0.350 |
Why?
|
| MAP Kinase Signaling System | 5 | 2011 | 887 | 0.340 |
Why?
|
| Indoles | 2 | 2015 | 1035 | 0.340 |
Why?
|
| Mice, Inbred NOD | 5 | 2020 | 911 | 0.340 |
Why?
|
| THP-1 Cells | 2 | 2020 | 54 | 0.340 |
Why?
|
| Humans | 69 | 2022 | 271076 | 0.330 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 2008 | 9 | 0.330 |
Why?
|
| Piperazines | 9 | 2021 | 2153 | 0.320 |
Why?
|
| MicroRNAs | 4 | 2020 | 2906 | 0.320 |
Why?
|
| Caspase 8 | 1 | 2008 | 151 | 0.310 |
Why?
|
| Animals | 32 | 2022 | 62871 | 0.310 |
Why?
|
| Mitogen-Activated Protein Kinases | 9 | 2014 | 687 | 0.300 |
Why?
|
| Protein Interaction Maps | 2 | 2019 | 150 | 0.300 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 774 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2018 | 843 | 0.290 |
Why?
|
| eIF-2 Kinase | 1 | 2008 | 166 | 0.290 |
Why?
|
| Blood Proteins | 2 | 2019 | 301 | 0.290 |
Why?
|
| Neoplasms | 7 | 2021 | 15838 | 0.290 |
Why?
|
| Cell Proliferation | 11 | 2021 | 7295 | 0.280 |
Why?
|
| Kidney Tubules | 1 | 2007 | 194 | 0.280 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2019 | 2633 | 0.280 |
Why?
|
| Remission Induction | 3 | 2018 | 3646 | 0.280 |
Why?
|
| Mice, SCID | 4 | 2020 | 1856 | 0.270 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10698 | 0.270 |
Why?
|
| Proto-Oncogene Proteins | 9 | 2015 | 2618 | 0.260 |
Why?
|
| HL-60 Cells | 8 | 2016 | 318 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 2399 | 0.240 |
Why?
|
| Proteomics | 3 | 2022 | 1435 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2017 | 1725 | 0.240 |
Why?
|
| Ischemia | 1 | 2007 | 404 | 0.230 |
Why?
|
| Lactones | 3 | 2003 | 93 | 0.230 |
Why?
|
| Platelet Aggregation | 2 | 2015 | 183 | 0.220 |
Why?
|
| Blotting, Western | 6 | 2015 | 3649 | 0.220 |
Why?
|
| Autophagy | 3 | 2016 | 920 | 0.220 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3919 | 0.220 |
Why?
|
| Blood Platelets | 3 | 2015 | 682 | 0.220 |
Why?
|
| Mice | 19 | 2022 | 35996 | 0.210 |
Why?
|
| Protein Biosynthesis | 2 | 2011 | 1037 | 0.210 |
Why?
|
| Cell Line | 8 | 2017 | 5439 | 0.190 |
Why?
|
| Etoposide | 4 | 2008 | 905 | 0.190 |
Why?
|
| Protein Kinases | 2 | 2003 | 917 | 0.190 |
Why?
|
| Prognosis | 9 | 2021 | 22463 | 0.190 |
Why?
|
| Bone Marrow | 2 | 2020 | 2434 | 0.190 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2021 | 44 | 0.190 |
Why?
|
| Enzyme Inhibitors | 7 | 2013 | 1986 | 0.180 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2021 | 162 | 0.180 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2008 | 350 | 0.180 |
Why?
|
| Gene Ontology | 1 | 2020 | 77 | 0.180 |
Why?
|
| Adenylate Kinase | 2 | 2021 | 36 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 1836 | 0.180 |
Why?
|
| ras Proteins | 2 | 2017 | 803 | 0.180 |
Why?
|
| Metals, Heavy | 1 | 2020 | 30 | 0.170 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 68 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 4 | 1997 | 184 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 9078 | 0.170 |
Why?
|
| Protein Phosphatase 1 | 2 | 2018 | 79 | 0.170 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 153 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2011 | 388 | 0.160 |
Why?
|
| Peptide Fragments | 2 | 2015 | 1330 | 0.160 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2017 | 1014 | 0.160 |
Why?
|
| Bortezomib | 1 | 2021 | 553 | 0.160 |
Why?
|
| Coculture Techniques | 2 | 2018 | 634 | 0.160 |
Why?
|
| Protein Interaction Mapping | 1 | 2019 | 169 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 65 | 0.160 |
Why?
|
| Cell Growth Processes | 1 | 2018 | 339 | 0.150 |
Why?
|
| Spleen | 1 | 2020 | 736 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2008 | 2899 | 0.150 |
Why?
|
| Drug Synergism | 3 | 2018 | 1369 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 3 | 2011 | 624 | 0.140 |
Why?
|
| Microscopy, Fluorescence | 3 | 2013 | 782 | 0.140 |
Why?
|
| Antagomirs | 1 | 2016 | 20 | 0.140 |
Why?
|
| Isoenzymes | 2 | 2000 | 666 | 0.140 |
Why?
|
| Tandem Repeat Sequences | 1 | 2017 | 202 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2021 | 569 | 0.140 |
Why?
|
| Enzyme Activation | 6 | 2015 | 1837 | 0.140 |
Why?
|
| Protein Transport | 4 | 2018 | 738 | 0.140 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 1995 | 36 | 0.140 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2016 | 36 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 4 | 1997 | 1773 | 0.130 |
Why?
|
| RNA, Messenger | 5 | 2020 | 6492 | 0.130 |
Why?
|
| Mutation | 5 | 2021 | 15855 | 0.130 |
Why?
|
| Flow Cytometry | 5 | 2015 | 3082 | 0.130 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2016 | 80 | 0.130 |
Why?
|
| Protein Kinase C beta | 2 | 2015 | 35 | 0.130 |
Why?
|
| Cell Adhesion | 2 | 2015 | 1046 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2015 | 80 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2018 | 505 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6249 | 0.120 |
Why?
|
| Heterografts | 1 | 2017 | 745 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 125 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 671 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 1019 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 443 | 0.120 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 352 | 0.120 |
Why?
|
| Protein Isoforms | 1 | 2017 | 860 | 0.120 |
Why?
|
| Acute Disease | 4 | 2014 | 2521 | 0.120 |
Why?
|
| bcl-X Protein | 3 | 2021 | 199 | 0.120 |
Why?
|
| Propylene Glycols | 1 | 2014 | 39 | 0.120 |
Why?
|
| K562 Cells | 3 | 2016 | 345 | 0.120 |
Why?
|
| Sphingosine | 1 | 2014 | 60 | 0.120 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2014 | 50 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2020 | 1229 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2020 | 2034 | 0.120 |
Why?
|
| Integrin alpha4beta1 | 1 | 2014 | 48 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1432 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 594 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 4 | 2004 | 301 | 0.110 |
Why?
|
| Cell Differentiation | 3 | 2018 | 4191 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 132 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2020 | 1030 | 0.110 |
Why?
|
| beta Catenin | 1 | 2017 | 690 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2016 | 441 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 515 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 154 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1215 | 0.110 |
Why?
|
| Graft vs Host Disease | 5 | 1997 | 2804 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 5233 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 467 | 0.110 |
Why?
|
| Computational Biology | 1 | 2019 | 1263 | 0.110 |
Why?
|
| Bcl-2-Like Protein 11 | 3 | 2011 | 69 | 0.100 |
Why?
|
| Lung Neoplasms | 4 | 2016 | 11758 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 7 | 2011 | 380 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 527 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2008 | 896 | 0.100 |
Why?
|
| Male | 12 | 2021 | 128555 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2015 | 1604 | 0.100 |
Why?
|
| Cytoskeletal Proteins | 1 | 2014 | 542 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 5112 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 487 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2019 | 1144 | 0.090 |
Why?
|
| Sp3 Transcription Factor | 1 | 2010 | 15 | 0.090 |
Why?
|
| raf Kinases | 1 | 2011 | 81 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 2471 | 0.090 |
Why?
|
| Female | 17 | 2021 | 148608 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 211 | 0.090 |
Why?
|
| Staurosporine | 3 | 2001 | 150 | 0.090 |
Why?
|
| Berberine | 2 | 2021 | 13 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 357 | 0.090 |
Why?
|
| Piperidines | 1 | 2016 | 1089 | 0.090 |
Why?
|
| Cell Cycle | 4 | 2018 | 2151 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 746 | 0.090 |
Why?
|
| Rats | 6 | 2007 | 6661 | 0.090 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2011 | 815 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2004 | 280 | 0.090 |
Why?
|
| Sp1 Transcription Factor | 1 | 2010 | 193 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 10349 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 5324 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2010 | 2126 | 0.080 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 642 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 4394 | 0.080 |
Why?
|
| Membrane Proteins | 3 | 2011 | 2953 | 0.080 |
Why?
|
| Benzamides | 3 | 2011 | 1883 | 0.080 |
Why?
|
| Models, Biological | 3 | 2014 | 3227 | 0.080 |
Why?
|
| Kava | 1 | 2008 | 9 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2474 | 0.080 |
Why?
|
| T-Lymphocytes | 3 | 1997 | 3929 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 2125 | 0.080 |
Why?
|
| Bryostatins | 3 | 2003 | 14 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2008 | 85 | 0.080 |
Why?
|
| Stem Cells | 1 | 2015 | 1229 | 0.080 |
Why?
|
| Aged | 7 | 2021 | 73177 | 0.080 |
Why?
|
| p21-Activated Kinases | 1 | 2008 | 131 | 0.080 |
Why?
|
| Macrolides | 3 | 2003 | 65 | 0.080 |
Why?
|
| Middle Aged | 8 | 2021 | 90070 | 0.080 |
Why?
|
| DNA Damage | 1 | 2016 | 1980 | 0.070 |
Why?
|
| Imatinib Mesylate | 2 | 2008 | 1691 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2011 | 1571 | 0.070 |
Why?
|
| Annexin A1 | 1 | 2007 | 41 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2014 | 1583 | 0.070 |
Why?
|
| Survival Analysis | 2 | 2017 | 9309 | 0.070 |
Why?
|
| Transfection | 3 | 2002 | 3172 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 658 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2008 | 226 | 0.070 |
Why?
|
| Nitric Oxide | 2 | 2007 | 664 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1575 | 0.070 |
Why?
|
| Interleukin-3 | 3 | 2001 | 106 | 0.070 |
Why?
|
| Protein Kinase C-delta | 1 | 2006 | 42 | 0.070 |
Why?
|
| Cyclosporine | 3 | 1995 | 296 | 0.070 |
Why?
|
| Dimerization | 2 | 2006 | 318 | 0.070 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 215 | 0.060 |
Why?
|
| Salvage Therapy | 1 | 2014 | 2117 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1269 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 30937 | 0.060 |
Why?
|
| Triterpenes | 1 | 2005 | 68 | 0.060 |
Why?
|
| Cytarabine | 4 | 2014 | 2014 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 593 | 0.060 |
Why?
|
| Benzopyrans | 1 | 2004 | 43 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1955 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 320 | 0.060 |
Why?
|
| Macrophages | 2 | 2007 | 1369 | 0.060 |
Why?
|
| Adenoma | 1 | 2008 | 741 | 0.060 |
Why?
|
| Cell Physiological Phenomena | 1 | 2003 | 25 | 0.060 |
Why?
|
| Aldehyde Reductase | 1 | 2003 | 23 | 0.050 |
Why?
|
| Pyrimidines | 3 | 2016 | 3667 | 0.050 |
Why?
|
| Enzymes | 1 | 2003 | 72 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2008 | 1182 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5161 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2006 | 1502 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2007 | 627 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 1997 | 595 | 0.050 |
Why?
|
| Mollusca | 1 | 2002 | 14 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2007 | 1184 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2021 | 3138 | 0.050 |
Why?
|
| Adult | 6 | 2020 | 81614 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3417 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 16184 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 362 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 213 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2018 | 834 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2007 | 802 | 0.050 |
Why?
|
| Stromal Cells | 2 | 2016 | 840 | 0.050 |
Why?
|
| Thiadiazoles | 1 | 2021 | 61 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2002 | 306 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 233 | 0.050 |
Why?
|
| Threonine | 1 | 2001 | 165 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2021 | 286 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 248 | 0.050 |
Why?
|
| Malaria | 1 | 2021 | 91 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1757 | 0.040 |
Why?
|
| Trace Elements | 1 | 2020 | 35 | 0.040 |
Why?
|
| Protein Binding | 2 | 2008 | 3537 | 0.040 |
Why?
|
| Plasmids | 1 | 2002 | 952 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 504 | 0.040 |
Why?
|
| Serine | 1 | 2001 | 396 | 0.040 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 2 | 2011 | 76 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 553 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6027 | 0.040 |
Why?
|
| Survival Rate | 2 | 2018 | 12519 | 0.040 |
Why?
|
| Nitriles | 1 | 2004 | 943 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 7816 | 0.040 |
Why?
|
| Drug Design | 2 | 2011 | 378 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2002 | 916 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 534 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2014 | 5784 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 791 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2020 | 433 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2001 | 492 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 730 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 16592 | 0.040 |
Why?
|
| Metformin | 1 | 2021 | 395 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2021 | 1984 | 0.030 |
Why?
|
| Dynamins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 259 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2021 | 1377 | 0.030 |
Why?
|
| Secretory Vesicles | 1 | 2015 | 41 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 245 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 167 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 2022 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 341 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 386 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2007 | 483 | 0.030 |
Why?
|
| U937 Cells | 1 | 2014 | 179 | 0.030 |
Why?
|
| Pruritus | 1 | 2014 | 89 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 532 | 0.030 |
Why?
|
| Transplantation, Autologous | 2 | 1995 | 2049 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 431 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2014 | 1344 | 0.030 |
Why?
|
| Autoimmunity | 1 | 1995 | 268 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1084 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 671 | 0.030 |
Why?
|
| Reactive Oxygen Species | 2 | 2008 | 1012 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2013 | 52 | 0.030 |
Why?
|
| Cytoplasmic Granules | 1 | 2013 | 87 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2346 | 0.030 |
Why?
|
| Cell Division | 2 | 2011 | 2718 | 0.030 |
Why?
|
| Lymphoma | 1 | 2001 | 1516 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 917 | 0.030 |
Why?
|
| Base Sequence | 2 | 2010 | 5500 | 0.030 |
Why?
|
| Cell Movement | 1 | 2020 | 2500 | 0.030 |
Why?
|
| Diphenylamine | 1 | 2011 | 17 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1934 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2013 | 206 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 1079 | 0.030 |
Why?
|
| Rats, Inbred Lew | 3 | 1997 | 119 | 0.020 |
Why?
|
| Exanthema | 1 | 2014 | 211 | 0.020 |
Why?
|
| Graft Survival | 1 | 1995 | 1098 | 0.020 |
Why?
|
| Transcription Initiation Site | 1 | 2010 | 47 | 0.020 |
Why?
|
| Pseudogenes | 1 | 2011 | 91 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 1567 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1995 | 884 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2014 | 615 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3555 | 0.020 |
Why?
|
| Gene Expression | 2 | 1995 | 3682 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 580 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 791 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1621 | 0.020 |
Why?
|
| Collagen | 1 | 2013 | 738 | 0.020 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2011 | 275 | 0.020 |
Why?
|
| Skin | 1 | 1995 | 1290 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6896 | 0.020 |
Why?
|
| Flavonoids | 2 | 2001 | 201 | 0.020 |
Why?
|
| Cisplatin | 1 | 2016 | 2493 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 2029 | 0.020 |
Why?
|
| Benzo(a)pyrene | 1 | 2008 | 38 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2008 | 49 | 0.020 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 388 | 0.020 |
Why?
|
| Pyridines | 1 | 2016 | 1312 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2008 | 109 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3459 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 811 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1045 | 0.020 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 1 | 2007 | 37 | 0.020 |
Why?
|
| Fenretinide | 1 | 2007 | 100 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2008 | 251 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 1719 | 0.020 |
Why?
|
| Depsipeptides | 1 | 2007 | 78 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2008 | 445 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 718 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 1473 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 255 | 0.020 |
Why?
|
| Eating | 1 | 2008 | 449 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 10250 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 162 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 33833 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2007 | 297 | 0.020 |
Why?
|
| Acetylation | 1 | 2007 | 519 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 958 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 704 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13920 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 559 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1995 | 191 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7464 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2007 | 459 | 0.010 |
Why?
|
| Child | 2 | 2021 | 30421 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2021 | 16981 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 4646 | 0.010 |
Why?
|
| Peptidyl Transferases | 1 | 2003 | 7 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2011 | 4360 | 0.010 |
Why?
|
| Cycloheximide | 1 | 2003 | 112 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 1337 | 0.010 |
Why?
|
| Nucleosides | 1 | 2003 | 63 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 800 | 0.010 |
Why?
|
| Transcription Factors | 2 | 2011 | 5494 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 1280 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2003 | 42 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3245 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 15256 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 6792 | 0.010 |
Why?
|
| Leukemia, Lymphoid | 1 | 2003 | 291 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 117 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 252 | 0.010 |
Why?
|
| Proteins | 1 | 2011 | 2049 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 7938 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 422 | 0.010 |
Why?
|
| Immunotherapy | 1 | 1995 | 3533 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2002 | 75 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2003 | 582 | 0.010 |
Why?
|
| Anisomycin | 1 | 2001 | 12 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 208 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 2001 | 32 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2001 | 46 | 0.010 |
Why?
|
| Retinoids | 1 | 2002 | 154 | 0.010 |
Why?
|
| Time Factors | 1 | 2015 | 13130 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 1666 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 342 | 0.010 |
Why?
|
| Aurintricarboxylic Acid | 1 | 2000 | 3 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2002 | 464 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 586 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 1372 | 0.010 |
Why?
|
| Histones | 1 | 2007 | 1510 | 0.010 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 641 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 22062 | 0.010 |
Why?
|
| Tretinoin | 1 | 2002 | 621 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2001 | 1011 | 0.010 |
Why?
|
| Blast Crisis | 1 | 2002 | 587 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2000 | 324 | 0.010 |
Why?
|
| Cytogenetic Analysis | 1 | 2000 | 574 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2000 | 616 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 1961 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 4067 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 3909 | 0.010 |
Why?
|
| Transplantation, Isogeneic | 1 | 1997 | 68 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 3076 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 1995 | 37 | 0.010 |
Why?
|
| Thymectomy | 1 | 1995 | 80 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1995 | 311 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1995 | 443 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2000 | 4332 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1997 | 1054 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1997 | 3497 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1997 | 1654 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1995 | 3043 | 0.000 |
Why?
|
| Heart Transplantation | 1 | 1995 | 908 | 0.000 |
Why?
|
| Liver | 1 | 1997 | 3127 | 0.000 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1995 | 1838 | 0.000 |
Why?
|
| Adolescent | 1 | 2000 | 32595 | 0.000 |
Why?
|